Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.

No Thumbnail Available

All Authors

Harnden, K.
Di Matteo, A.
Howell, K.
Mankia, K.

LTHT Author

Harnden, Kate
Di Matteo, Andrea
Howell, Keith
Mankia, Kulveer

LTHT Department

Rheumatology
Oncology
Haematology

Non Medic

Publication Date

2024

Item Type

Case Reports
Journal Article

Language

Subject

Subject Headings

Abstract

Immune checkpoint inhibitors have revolutionised the treatment of cancer. While very effective, they commonly cause a wide spectrum of immune-related adverse events. These immune-related adverse events can be fatal and often have significant effects on quality of life. They therefore require prompt recognition and management. We report the case of a woman presenting with widespread joint pain and stiffness 6 hours after her first pembrolizumab infusion. She had no joint swelling on physical examination but an ultrasound scan revealed widespread musculoskeletal inflammation, confirming the diagnosis of inflammatory arthritis. To the best of our knowledge, this is the fastest reported inflammatory arthritis onset following immune checkpoint inhibitor treatment. It highlights the importance of timely imaging in patients on immune checkpoint inhibitors who present with new non-specific musculoskeletal pain. Her symptoms improved dramatically with intramuscular triamcinolone injection.

Journal

BMJ Case Reports